Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.73 |
| ▸ | BCHE | P06276 | 3/20 | 0.69 |
| ▸ | ACHE | P22303 | 3/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 5/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PRKDC | P78527 | 1/20 | 0.61 |
| ▸ | BCL9 | O00512 | 1/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429221 | 0.97 | BCHE (0.74) | ABL1BCHEACHESIGMAR1EGFR | |
| SCHEMBL432219 | 0.96 | BCHE (0.73) | ABL1BCHEACHESIGMAR1EGFR | |
| SCHEMBL430405 | 0.91 | BCHE (0.70) | ABL1BCHEACHESIGMAR1EGFR | |
| SCHEMBL433773 | 0.90 | BCHE (0.72) | ABL1BCHEACHEEGFRRET | |
| SCHEMBL433259 | 0.88 | BCHE (0.75) | ABL1BCHEACHESIGMAR1EGFR | |
| SCHEMBL430406 | 0.87 | BCHE (0.74) | BCHEACHESIGMAR1EGFR | |
| SCHEMBL431805 | 0.87 | BCHE (0.77) | BCHEACHEEGFRRETKDR | |
| SCHEMBL432003 | 0.86 | BCHE (0.75) | BCHEACHEEGFRRETKDR | |
| SCHEMBL14463612 | 0.83 | ABL1 (0.54) | ABL1BCHEACHESIGMAR1BCL9 | |
| SCHEMBL12678185 | 0.81 | EGFR (0.80) | EGFRRETKDRABCB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642854-B2 | Flavanoid compounds and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20150174135-A1 | FLAVANOID COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2015-06-25 | — | — | US | disclosed |
| US-8969384-B2 | Flavonoid compounds and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-03-03 | — | — | US | disclosed |
| US-20120022062-A1 | Flavanoid Compounds and Process for Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-01-26 | — | — | US | disclosed |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-10 | — | — | US | disclosed |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-10 | — | — | US | disclosed |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-10 | — | — | US | disclosed |
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| EP-1976508-A2 | FLAVONOIDS ISOLATED FROM OROXYLUM INDICUM FOR TREATMENT OF GASTROINTESTINAL TOXICITY, ASSOCIATED SYMPTOMS AND ULCERS | Council of Scientific and Industrial Research (IN) | 2008-10-08 | — | — | EP | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
| WO-2007080484-A2 | FLAVONOIDS ISOLATED FROM OROXYLUM INDICUM FOR TREATMENT OF GASTROINTESTINAL TOXICITY, ASSOCIATED SYMPTOMS AND ULCERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174135-A1 | FLAVANOID COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | F2, FOXM1, HRH2 | ABL1 1767/4885BCHE 3957/4885ACHE 3382/4885 |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | MLN, FABP6, SI | ABL1 3050/4885BCHE 224/4885ACHE 418/4885 |
| US-20120022062-A1 | Flavanoid Compounds and Process for Preparation Thereof | F2, FOXM1, HRH2 | ABL1 1767/4885BCHE 3957/4885ACHE 3382/4885 |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | FABP6, MLN, SI | ABL1 2913/4885BCHE 209/4885ACHE 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.